Precipio Inc
$ 22.98
-1.84%
31 Dec - close price
- Market Cap 31,614,300 USD
- Current Price $ 22.98
- High / Low $ 23.49 / 22.50
- Stock P/E N/A
- Book Value 8.10
- EPS -1.19
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.15 %
- 52 Week High 28.50
- 52 Week Low 3.90
About
Precipio, Inc. is a leading oncology diagnostics and reagent technology firm headquartered in New Haven, Connecticut, dedicated to advancing cancer diagnosis and enhancing patient outcomes. The company leverages cutting-edge technologies to provide a comprehensive suite of diagnostic products and services tailored for U.S. healthcare providers in the oncology sector. By embodying the principles of precision medicine, Precipio strengthens treatment selection and monitoring processes, positioning itself as a pivotal entity in the transformative landscape of cancer care.
Analyst Target Price
$19.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-13 | 2025-05-12 | 2025-03-31 | 2024-11-11 | 2024-08-13 | 2024-05-14 | 2023-11-13 | 2023-08-11 | 2023-05-12 | 2023-03-30 | 2022-11-10 |
| Reported EPS | -0.05 | 0.05 | -0.5883 | -0.2444 | -0.4229 | -0.8336 | 0.6514 | -1.04 | -0.09 | -0.13 | -0.1 | -0.14 |
| Estimated EPS | None | None | None | 0.74 | None | None | None | -1.21 | -0.1 | -0.13 | -0.14 | -0.04 |
| Surprise | 0 | 0 | 0 | -0.9844 | 0 | 0 | 0 | 0.17 | 0.01 | 0 | 0.04 | -0.1 |
| Surprise Percentage | None% | None% | None% | -133.027% | None% | None% | None% | 14.0496% | 10% | 0% | 28.5714% | -250% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRPO
2025-12-31 07:08:45
Precipio, Inc. has achieved a remarkable 351.85% return over the past year, leading the Pharmaceuticals & Biotechnology sector, with Evoke Pharma, Inc. also showing strong performance at 124.95%. Both are Micro Cap companies. Other notable performers include Monster Beverage Corp. in Beverages, RF Industries Ltd. in Electronics & Appliances, and DLocal Ltd. in Software Products, highlighting diverse investment opportunities across sectors.
2025-12-25 09:58:00
This article analyzes Precipio Inc. (NASDAQ: PRPO), noting weak near and mid-term sentiment despite a long-term positive outlook. It identifies an exceptional 56.0:1 risk-reward setup targeting a 17.3% gain against a 0.3% risk. The piece outlines three AI-generated institutional trading strategies for PRPO, tailored for different risk profiles and holding periods, including position, momentum breakout, and risk hedging strategies.
2025-12-14 08:04:00
This article analyzes Precipio Inc. (NASDAQ: PRPO) movements, highlighting neutral near and mid-term readings that could moderate a long-term positive bias. It identifies an exceptional 57.4:1 risk-reward short setup and outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also provides multi-timeframe signal strengths and support/resistance levels for PRPO.
2025-12-05 10:00:00
Precipio, Inc. (NASDAQ: PRPO) will present findings from a joint study with Memorial Sloan Kettering Cancer Center at the 2025 ASH meeting. The study, involving 895 patient samples, demonstrates the superior performance of Precipio's BCR::ABL1 assay, showing clear positive impacts on patient care and laboratory workflow improvements. The presentation is scheduled for December 8th at the ASH Meeting in Orlando, Florida.
2025-12-05 04:43:39
Precipio (NASDAQ:PRPO) announced a limited unauthorized access to a specific data folder in its secure cloud environment on December 4, 2025. The company confirmed that the breach was restricted to historical customer service files and did not expose patient Social Security numbers, addresses, financial data, or proprietary company information. Precipio anticipates that incident-related costs will be covered by its cybersecurity insurance and does not foresee any material impact on its operations, patients, or finances.
2025-12-05 03:43:39
Precipio, Inc. will present findings from a joint study with Memorial Sloan Kettering at the ASH Meeting on December 8, 2025. The study showcases Precipio's BCR::ABL1 assay's superior performance over two leading platforms across 895 patient samples, demonstrating positive impacts on patient care and laboratory workflows. The company aims to reduce cancer misdiagnoses through its innovative diagnostic products and services.
